A single-arm feasibility phase II study of EMF (erlotinib + methotrexate + 5-fluorouracil) regimen in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is a huge burden in India with the majority of patients presenting in advanced unresectable stages. Innovative, low-cost but efficacious regimens that can be easily administered in the outpatient setting are the need of the hour. We envisaged...

Descripción completa

Detalles Bibliográficos
Autores principales: Baa, Annie Kanchan, Sharma, Atul, Bhaskar, Suman, Biswas, Ahitagni, JeeBharti, Sacchidanand, Thakar, Alok, Kumar, Rajeev, Pramanik, Raja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666288/
https://www.ncbi.nlm.nih.gov/pubmed/36405947
http://dx.doi.org/10.3332/ecancer.2022.1451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666288/
https://www.ncbi.nlm.nih.gov/pubmed/36405947
http://dx.doi.org/10.3332/ecancer.2022.1451

Ejemplares similares